Trial Profile

A Phase II/III, Extension Study of Orally Administered PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 04 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Deucrictibant (Primary)
Indications Hereditary angioedema
Focus Adverse reactions
Acronyms RAPIDe-2
Sponsors Pharvaris

Most Recent Events

27 Jun 2025 According to a Pharvaris media release, data from this trial will be presented at the US Hereditary Angioedema Association's 2025 National Summit to be held from July 10-13, 2025, in Baltimore, Maryland.
16 Jun 2025 Results presented in the Pharvaris Media Release.
16 Jun 2025 According to a Pharvaris media release, results from this trial were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com